Is NURPF or JEPQ a better dividend investment in 2026?

NURPF currently yields 24.33% with a 5% 5-year dividend growth rate. JEPQ yields 11.10% with 5% growth. The better choice depends on your goal: NURPF offers higher current income.

What is the dividend yield difference between NURPF and JEPQ?

NURPF has a forward dividend yield of 24.33% ($2.00/share annually). JEPQ yields 11.10% ($6.16/share annually). The yield gap is 13.23 percentage points.

Home › Compare › NURPF vs JEPQ

NURPF vs JEPQ: Dividend Comparison 2026

NURPF yields 24.33% · JEPQ yields 11.10%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 NURPF wins by $50.1K in total portfolio value

INVESTMENT

TIME HORIZON10 years

NURPF

● Live price

24.33%

Share price

$8.22

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$94.9K

Annual income

$10,445.94

Full NURPF calculator →

JEPQ

JPMorgan Nasdaq Equity Premium Income ETF

● Live price

11.10%

Share price

$55.52

Annual div

$6.16

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.8K

Annual income

$2,152.59

Full JEPQ calculator →

Portfolio growth — NURPF vs JEPQ

📍 NURPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	NURPF	JEPQ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, NURPF + JEPQ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

NURPF pays

JEPQ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NURPF

Annual income on $10K today (after 15% tax)

$2,068.13/yr

After 10yr DRIP, annual income (after tax)

$8,879.05/yr

JEPQ

Annual income on $10K today (after 15% tax)

$943.83/yr

After 10yr DRIP, annual income (after tax)

$1,829.70/yr

At 15% tax rate, NURPF beats the other by $7,049.35/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NURPF + JEPQ for your $10,000?

NURPF: 50%JEPQ: 50%

100% JEPQ50/50100% NURPF

Portfolio after 10yr

$69.8K

Annual income

$6,299.26/yr

Blended yield

9.02%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NURPF buys

JEPQ buys

No recent congressional trades found for NURPF or JEPQ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricNURPFJEPQ

Forward yield	24.33% ✓	11.10%
Annual dividend / share	$2.00	$6.16 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$94.9K ✓	$44.8K
Annual income after 10y	$10,445.94 ✓	$2,152.59
Total dividends collected	$59.3K ✓	$16.3K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: NURPF vs JEPQ ($10,000, DRIP)

Year	NURPF Portfolio	NURPF Income/yr	JEPQ Portfolio	JEPQ Income/yr	Gap
1← crossover	$13,133	$2,433.09	$11,930	$1,110.39	+$1.2K → NURPF
2	$17,039	$2,986.35	$14,133	$1,224.34	+$2.9K → NURPF
3	$21,852	$3,621.00	$16,632	$1,340.46	+$5.2K → NURPF
4	$27,722	$4,340.18	$19,454	$1,457.97	+$8.3K → NURPF
5	$34,809	$5,145.80	$22,626	$1,576.08	+$12.2K → NURPF
6	$43,284	$6,038.47	$26,175	$1,694.09	+$17.1K → NURPF
7	$53,331	$7,017.47	$30,133	$1,811.32	+$23.2K → NURPF
8	$65,145	$8,080.76	$34,531	$1,927.17	+$30.6K → NURPF
9	$78,930	$9,225.06	$39,403	$2,041.08	+$39.5K → NURPF
10	$94,901	$10,445.94	$44,787	$2,152.59	+$50.1K → NURPF

NURPF vs JEPQ: Complete Analysis 2026

NURPF — Stock

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Full NURPF Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →

📬

Get this NURPF vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NURPF vs SCHD NURPF vs JEPI NURPF vs O NURPF vs KO NURPF vs MAIN NURPF vs XYLD NURPF vs QYLD NURPF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.